Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H7N3 pLAIV Priming Followed by H7N9 pIIV in Healthy Adults
NCT03581903Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of live influenza A vaccine H7N3 (6-2) AA ca recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)-National Institute of Allergy and Infectious Diseases (NIAID)-avian influenza H7N3 infection and monovalent inactivated influenza A/H7N9 virus vaccine, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Hemagglutination-inhibition (HAI) antibody response to H7N9 virus following administration of pIIV. Started Sep 2017; status: completed.
02
Drugs
live influenza A vaccine H7N3 (6-2) AA ca recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)-National Institute of Allergy and Infectious Diseases (NIAID)-avian influenza H7N3 infectionmonovalent inactivated influenza A/H7N9 virus vaccine
Beyond the preview
Go deeper on NCT03581903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581903.